Entropy Technologies LP Buys 14,741 Shares of IDEXX Laboratories, Inc. $IDXX

Entropy Technologies LP grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 709.0% in the first quarter, HoldingsChannel.com reports. The fund owned 16,820 shares of the company’s stock after acquiring an additional 14,741 shares during the quarter. Entropy Technologies LP’s holdings in IDEXX Laboratories were worth $9,451,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Empowered Funds LLC increased its position in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after purchasing an additional 95 shares during the period. Sivia Capital Partners LLC bought a new stake in IDEXX Laboratories during the second quarter worth about $265,000. Jump Financial LLC lifted its position in IDEXX Laboratories by 1,006.4% during the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after purchasing an additional 5,032 shares during the period. Cary Street Partners Financial LLC acquired a new stake in IDEXX Laboratories during the second quarter worth about $164,000. Finally, Sei Investments Co. grew its stake in IDEXX Laboratories by 218.7% during the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after buying an additional 82,755 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent analyst reports. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Citigroup assumed coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Finally, UBS Group lowered their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Up 0.9%

Shares of NASDAQ IDXX opened at $544.32 on Friday. The company has a market cap of $42.94 billion, a price-to-earnings ratio of 40.08, a PEG ratio of 2.95 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98. The stock has a 50-day moving average price of $556.27 and a two-hundred day moving average price of $595.41.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the company posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.